Impax Asset Management’s Integra LifeSciences IART Stock Holding History

Impax Asset Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-419,883	Closed	-$17.7M	–	195
2017 Q1	$17.7M	Buy	419,883 +11,327	+3%	+$484K	0.99%	38
2016 Q4	$17.5M	Buy	408,556 +248,034	+155%	+$10.1M	1%	38
2016 Q3	$6.63M	Sell	160,522 -50,000	-24%	-$2.09M	0.38%	94
2016 Q2	$8.4M	Hold	210,522	–	–	0.49%	86
2016 Q1	$7.09M	Buy	+210,522	New	+$6.56M	0.38%	86

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Impax Asset Management's IART Position: Q2 2017 in Review

Impax Asset Management sold out of Integra LifeSciences (IART) in Q2 2017, closing a stake of 419,883 shares — an estimated $17.7M sold.

Impax Asset Management first reported a position in IART in Q1 2016 and held it in 5 quarters. The position peaked at $17.7M in Q1 2017. 223 funds tracked by Wall St. Rank hold IART as of Q2 2017.

Impax Asset Management reported no remaining Integra LifeSciences position as of Q2 2017 after selling out during the quarter.
Impax Asset Management sold 419,883 Integra LifeSciences shares in Q2 2017, an estimated $17.7M.
Impax Asset Management first reported a position in Integra LifeSciences in Q1 2016 and held it in 5 quarters.
Impax Asset Management's Integra LifeSciences position peaked at $17.7M in Q1 2017.
223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2017.

Based on Impax Asset Management's 13F filing for Q2 2017, filed 4 Aug 2017.